Prognostic significance of SOX17 and WNT5a promoter methylation status in circulating cell-free DNA metastatic colorectal cancer patients.

IF 0.3 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Hippokratia Pub Date : 2023-01-01

A Vagionas, I Balgkouranidou, T Koukaki, E Biziota, K Amarantidis, S Kakolyris, N Xenidis

{"title":"Prognostic significance of SOX17 and WNT5a promoter methylation status in circulating cell-free DNA metastatic colorectal cancer patients.","authors":"A Vagionas, I Balgkouranidou, T Koukaki, E Biziota, K Amarantidis, S Kakolyris, N Xenidis","doi":"","DOIUrl":null,"url":null,"abstract":"Aim: Carcinogenesis of colorectal cancer is a process involving genetic mutations and epigenetic alterations in its multiple phases. The most considerable epigenetic alteration occurring in colorectal cancer (CRC) tumorigenesis is the methylation-mediated silencing of tumor suppressor genes. The present study aimed to detect the methylation status of SOX17 and WNT5a promoters in cell-free DNA circulating in plasma of metastatic CRC patients and to investigate potential prognostic correlation.Methods: A methylation-specific real-time polymerase chain reaction was utilized to investigate the methylation status of genes (SOX17 and WNT5a) promoter in the blood of 85 metastatic CRC patients.Results: We found the SOX17 promoter methylated in 54/85 (63.5 %) while WNT5a was methylated in 39/85 (45.8 %) samples of the advanced CRC. All control samples were negative for SOX17 and WNT5a promoter methylation. Patients with metastatic CRC and methylated SOX17 and WNT5a promoter status had a significantly poorer outcome than patients with non-methylated ones.Conclusions: Plasma SOX17 and WNT5a promoter methylation are frequent epigenetic events in advanced CRC. The reported correlations between the methylation status of genes (SOX17 and Wnt5a) promoter and poorer survival in patients with advanced CRC disease agree with the proposed role of SOX17 as a tumor suppressor gene. A more considerable CRC patient cohort is required to research these findings' potential further and investigate whether SOX17 in plasma could serve as a useful prognostic biomarker in metastatic CRC. HIPPOKRATIA 2023, 27 (1):7-11.","PeriodicalId":50405,"journal":{"name":"Hippokratia","volume":"27 1","pages":"7-11"},"PeriodicalIF":0.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10908310/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hippokratia","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Carcinogenesis of colorectal cancer is a process involving genetic mutations and epigenetic alterations in its multiple phases. The most considerable epigenetic alteration occurring in colorectal cancer (CRC) tumorigenesis is the methylation-mediated silencing of tumor suppressor genes. The present study aimed to detect the methylation status of SOX17 and WNT5a promoters in cell-free DNA circulating in plasma of metastatic CRC patients and to investigate potential prognostic correlation.

Methods: A methylation-specific real-time polymerase chain reaction was utilized to investigate the methylation status of genes (SOX17 and WNT5a) promoter in the blood of 85 metastatic CRC patients.

Results: We found the SOX17 promoter methylated in 54/85 (63.5 %) while WNT5a was methylated in 39/85 (45.8 %) samples of the advanced CRC. All control samples were negative for SOX17 and WNT5a promoter methylation. Patients with metastatic CRC and methylated SOX17 and WNT5a promoter status had a significantly poorer outcome than patients with non-methylated ones.

Conclusions: Plasma SOX17 and WNT5a promoter methylation are frequent epigenetic events in advanced CRC. The reported correlations between the methylation status of genes (SOX17 and Wnt5a) promoter and poorer survival in patients with advanced CRC disease agree with the proposed role of SOX17 as a tumor suppressor gene. A more considerable CRC patient cohort is required to research these findings' potential further and investigate whether SOX17 in plasma could serve as a useful prognostic biomarker in metastatic CRC. HIPPOKRATIA 2023, 27 (1):7-11.

本刊更多论文

循环细胞游离 DNA 转移性结直肠癌患者 SOX17 和 WNT5a 启动子甲基化状态的预后意义

目的：结直肠癌的致癌过程涉及基因突变和表观遗传学改变的多个阶段。大肠癌（CRC）肿瘤发生过程中最重要的表观遗传学改变是甲基化介导的抑癌基因沉默。本研究旨在检测转移性 CRC 患者血浆中循环的无细胞 DNA 中 SOX17 和 WNT5a 启动子的甲基化状态，并研究潜在的预后相关性：方法：采用甲基化特异性实时聚合酶链反应研究85例转移性CRC患者血液中基因（SOX17和WNT5a）启动子的甲基化状态：结果：我们发现在54/85（63.5%）例晚期CRC样本中SOX17启动子发生了甲基化，而在39/85（45.8%）例样本中WNT5a发生了甲基化。所有对照样本的 SOX17 和 WNT5a 启动子甲基化均为阴性。转移性CRC患者的SOX17和WNT5a启动子甲基化状况明显差于未甲基化的患者：结论：血浆SOX17和WNT5a启动子甲基化是晚期CRC的常见表观遗传学事件。所报道的基因（SOX17 和 Wnt5a）启动子甲基化状态与晚期 CRC 患者较差的生存率之间的相关性与所提出的 SOX17 作为肿瘤抑制基因的作用相吻合。要进一步研究这些发现的潜力，并探讨血浆中的 SOX17 是否可作为转移性 CRC 的有用预后生物标志物，还需要更多的 CRC 患者群。Hippokratia 2023, 27 (1):7-11.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hippokratia MEDICINE, GENERAL & INTERNAL-

CiteScore

1.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Hippokratia journal is a quarterly issued, open access, peer reviewed, general medical journal, published in Thessaloniki, Greece. It is a forum for all medical specialties. The journal is published continuously since 1997, its official language is English and all submitted manuscripts undergo peer review by two independent reviewers, assigned by the Editor (double blinded review process). Hippokratia journal is managed by its Editorial Board and has an International Advisory Committee and over 500 expert Reviewers covering all medical specialties and additionally Technical Reviewers, Statisticians, Image processing Experts and a journal Secretary. The Society “Friends of Hippokratia Journal” has the financial management of both the printed and electronic edition of the journal.